Page 1 | Search Results | Blood Advances | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-1 of 1

Sort by

Sort Order Select

Journal Articles

Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia

Danielle S. Wallace, Clive S. Zent, Andrea M. Baran, Patrick M. Reagan, Carla Casulo, Geoffrey Rice, Jonathan W. Friedberg, Paul M. Barr

Blood Adv (2023) 7 (11): 2496–2503.

https://doi.org/10.1182/bloodadvances.2022009382

Published: 2023

Includes: Supplemental data